Xeris Biopharma (XERS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.18
- EPS estimate
- $0.01
- EPS surprise
- −1587.60%
- Revenue surprise
- +0.98%
- Revenue
- $91.0M
- Revenue estimate
- $90.1M
- Reported
- Aug 6, 2026
Xeris Biopharma reported Q2 2026 results on August 6, 2026, posting a loss of $0.18 per share. Analysts had expected a small profit of $0.01, so the source records a 1,587.60% miss. Revenue was $91.0 million, 0.98% above the $90.1 million estimate. A year earlier, Q2 2025 brought a $0.01 loss on $71.5 million in revenue, so sales rose about 27% while the loss widened.
Revenue growth is the clearest trend in the table. Annual revenue climbed every year, from $109.3 million in 2022 to $289.2 million in 2025, about 2.6 times as much. The annual loss narrowed at the same time, from $0.70 per share in 2022 to $0.45, $0.38 and finally $0.01 in 2025. Q4 2025 earned $0.06 and Q1 2026 earned $0.01, the only profitable quarters shown, so the Q2 loss broke that short run. Q2 2026 revenue was the highest in the table. Over the last 20 quarters, Xeris beat the EPS estimate eight times.
Q3 results arrived between November 6 and November 10 in each of the past five years. That points to early November 2026 for the next report. It will show whether the company returns to a profit on the higher revenue base.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | $0.01 | −$0.18 | −1587.60% | $91.0M | SEC |
| Q1 2026 | May 7, 2026 | −$0.00 | $0.01 | +470.37% | $82.5M | SEC |
| Q4 2025 | Mar 2, 2026 | $0.03 | $0.06 | +116.61% | $85.8M | SEC |
| Q3 2025 | Nov 6, 2025 | $0.01 | $0.00 | −100.00% | $74.1M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.03 | −$0.01 | +64.29% | $71.5M | SEC |
| Q1 2025 | May 8, 2025 | −$0.05 | −$0.06 | −21.21% | $57.8M | SEC |
| Q4 2024 | Mar 6, 2025 | −$0.06 | −$0.03 | +46.24% | $57.0M | SEC |
| Q3 2024 | Nov 8, 2024 | −$0.09 | −$0.11 | −26.87% | $52.9M | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.10 | −$0.10 | −3.09% | $46.5M | SEC |
| Q1 2024 | May 9, 2024 | −$0.11 | −$0.14 | −32.08% | $40.3M | SEC |
| Q4 2023 | Mar 6, 2024 | −$0.09 | −$0.10 | −16.96% | $42.5M | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.10 | −$0.09 | +13.96% | $48.3M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.12 | −$0.14 | −21.74% | $36.9M | SEC |
| Q1 2023 | May 9, 2023 | −$0.16 | −$0.12 | +23.81% | $32.3M | SEC |
| Q4 2022 | Mar 8, 2023 | −$0.15 | −$0.10 | +32.75% | $32.5M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.15 | −$0.16 | −3.43% | $29.6M | SEC |
| Q2 2022 | Aug 10, 2022 | −$0.22 | −$0.19 | +12.32% | $25.3M | SEC |
| Q1 2022 | May 11, 2022 | −$0.24 | −$0.25 | −2.75% | $21.9M | SEC |
| Q4 2021 | Mar 10, 2022 | −$0.21 | −$0.42 | −100.00% | $21.4M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.34 | −$0.39 | −13.87% | $11.0M | SEC |
Quarterly revenue
Frequently asked questions
When did Xeris Biopharma (XERS) last report earnings?
Xeris Biopharma last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did XERS beat earnings estimates?
No. Xeris Biopharma reported EPS of −$0.18 for Q2 2026 against a $0.01 estimate — a 1587.60% miss.
How much revenue did XERS report last quarter?
Xeris Biopharma reported $91.0M in revenue for Q2 2026, against a consensus estimate of $90.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.